


Healthcare Industry News: HIV/AIDS
News Release - December 11, 2007
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
Source: Gilead Sciences
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
